Lung carcinogenesis by tobacco smoke

International Journal of Cancer

Volumn 131, Issue 12, 2012, Pages 2724-2732

  Hecht, Stephen S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

carcinogens; DNA adducts; nicotine; tobacco smoke

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; ANTIINFLAMMATORY AGENT; BENZO[A]PYRENE; BENZO[A]PYRENE 7,8 DIHYDRODIOL 9,10 OXIDE; CARCINOGEN; CIGARETTE SMOKE; COCARCINOGEN; DNA; K RAS PROTEIN; NICOTINE; NICOTINIC RECEPTOR; PHENANTHRENE TETRAOL; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; TOXIC SUBSTANCE; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGEN DNA INTERACTION; CHEMICAL MUTAGENESIS; CHRNA3 GENE; CHRNA5 GENE; GENOTOXICITY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; SMOKING; TUMOR PROMOTION;

CELL TRANSFORMATION, NEOPLASTIC; COCARCINOGENESIS; DNA ADDUCTS; HUMANS; LUNG; LUNG NEOPLASMS; MUTATION; NICOTINE; SMOKE; TOBACCO;

EID: 84867840442     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27816     Document Type: Article

References (91)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics 2012. CA Caner J Clin 2012; 62: 10-29.
2. International Agency for Research on Cancer. tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 83. Lyon, France: IARC, 2004. 33-1187.
3. Shafey, O, Eriksen, MP, Ross, H, et al. The tobacco atlas, 3rd edn. Atlanta, GA: American Cancer Society and World Lung Foundation, 2009. 19 p.
4. Hecht SS,. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91: 1194-210.
5. Rodgman A, Perfetti T, The chemical components of tobacco and tobacco smoke. Boca Raton, FL: CRC Press, 2009. 1483-784.
6. Hecht SS,. Research opportunities related to establishing standards for tobacco products under the family smoking prevention and tobacco control act. Nicotine Tob Res 2012; 14: 18-28.
7. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75.
8. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 184-90.
9. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-7.
10. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8.
11. Chen RJ, Chang LW, Lin P, et al. Epigenetic effects and molecular mechanisms of tumorigenesis induced by cigarette smoke: an overview. J Oncol 2011; 2011: 654931.
12. Takahashi H, Ogata H, Nishigaki R, et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKβ- and JNK1-dependent inflammation. Cancer Cell 2010; 17: 89-97.
13. Murphy SE, von Weymarn LB, Schutten MM, et al. Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone- induced lung tumorigenesis. Cancer Prev Res (Phila) 2011; 4: 1752-60.
14. Maier CR, Hollander MC, Hobbs EA, et al. Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev Res (Phila) 2011; 4: 1743-51.
15. Stoner GD, Shimkin MB,. Strain A mouse lung tumor bioassay. J Amer Coll Toxicol 1982; 1: 145-69.
16. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452: 638-42.
17. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008; 40: 616-22.
18. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452: 633-7.
19. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 2007; 16: 36-49.
20. Saccone NL, Wang JC, Breslau N, et al. The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res 2009; 69: 6848-56.
21. Saccone NL, Culverhouse RC, Schwantes-An TH, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet 2010; 6: e1001053.
22. Ware JJ, van den Bree MB, Munafo MR,. Association of the CHRNA5-A3-B4 gene cluster with heaviness of smoking: a meta-analysis. Nicotine Tob Res 2011; 13: 1167-75.
23. Timofeeva MN, McKay JD, Smith GD, et al. Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol Biomarkers Prev 2011; 20: 2250-61.
24. Wang Y, Broderick P, Matakidou A, et al. Chromosome 15q25 (CHRNA3-CHRNA5) variation impacts indirectly on lung cancer risk. PLoS One 2011; 6: e19085.
25. Wassenaar CA, Dong Q, Wei Q, et al. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011; 103: 1342-6.
26. Le Marchand L, Derby KS, Murphy SE, et al. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res 2008; 68: 9137-40.
27. Hecht SS,. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998; 11: 559-603.
28. Yuan J-M, Gao Y-T, Murphy SE, et al. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res 2011; 71: 6749-57.
29. Yuan JM, Gao YT, Wang R, et al. Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokers. Carcinogenesis 2012; 33: 804-9.
30. Ray R, Tyndale RF, Lerman C,. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 2009; 23: 252-61.
31. Benowitz NL,. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009; 49: 57-71.
32. Hecht SS, Tobacco smoke carcinogens and lung cancer. In:, Penning TM, ed. Chemical carcinogenesis. New York: Springer, 53-74.
33. International Agency for Research on Cancer. Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 92. Lyon, France: IARC, 2010. 35-818.
34. International Agency for Research on Cancer. Smokeless tobacco and tobacco-specific nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 89. Lyon, France: IARC, 2007. 421-583.
35. Dipple A, Moschel RC, Bigger CAH, Polynuclear aromatic hydrocarbons. In:, Searle CE, ed. Chemical carcinogens, 2nd edn., ACS monograph 182, vol. 1. Washington, D.C.: American Chemical Society, 1984. 41-163.
36. Luch A, Baird WM,. Metabolic activation and detoxification of polycyclic aromatic hydrocarbons. In:, Luch A, ed. The carcinogenic effects of polycyclic aromatic hydrocarbons, London: Imperial College Press, 2005. 19-96.
37. Hecht SS,. Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 2008; 21: 160-71.
38. Weng Y, Fang C, Turesky RJ, et al. Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. Cancer Res 2007; 67: 7825-32.
39. Hollander MC, Zhou X, Maier CR, et al. A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. Carcinogenesis 2011; 32: 1279-84.
40. Hecht SS,. More than 500 trillion molecules of strong carcinogens per cigarette: use in product labelling? 2011; 20: 387.
41. Hecht SS,. Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. Carcinogenesis 2005; 26: 1488-92.
42. Stinn W, Arts JH, Buettner A, et al. Murine lung tumor response after exposure to cigarette mainstream smoke or its particulate and gas/vapor phase fractions. Toxicology 2010; 275: 10-20.
43. International Agency for Research on Cancer. Tobacco smoking. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol. 38. Lyon, France: IARC, 1986. 37-375.
44. Gordon T, Bosland M,. Strain-dependent differences in susceptibility to lung cancer in inbred mice exposed to mainstream cigarette smoke. Cancer Lett 2009; 275: 213-20.
45. Hoffmann D, Schmeltz I, Hecht SS, et al, Tobacco carcinogenesis. In:, Gelboin H, Ts'o POP, eds. Polycyclic hydrocarbons and cancer, New York: Academic Press, 1978. 85-117.
46. Snook ME, Severson RF, Arrendale RF, et al. Multi-alkyated polynuclear aromatic hydrocarbons of tobacco smoke: separation and identification. J Natl Cancer Inst 1978; 9: 222-47.
47. Snook ME, Severson RF, Arrendale RF, et al. The identification of high molecular weight polynuclear aromatic hydrocarbons in a biologically active fraction of cigarette smoke condensate. Beiträge zur Tabakforschung 1977; 9: 79-101.
48. Rodgman A, Perfetti TA,. The composition of cigarette smoke: a catalogue of the polycyclic aromatic hydrocarbons. Beitr Tabakforschung Intl 2006; 22: 13-69.
49. Van Duuren BL, Goldschmidt BM,. Cocarcinogenic and tumor-promoting agents in tobacco carcinogenesis. J Natl Cancer Inst 1976; 56: 1237-42.
50. Hecht SS, Carmella S, Mori H, et al. Role of catechol as a major cocarcinogen in the weakly acidic fraction of smoke condensate. J Natl Cancer Inst 1981; 66: 163-9.
51. Melikian AA, Jordan KG, Braley J, et al. Effects of catechol on the induction of tumors in mouse skin by 7,8-dihydroxy-7,8-dihydrobenzo[a]pyrenes. Carcinogenesis 1989; 10: 1897-900.
52. Carmella SG, Hecht SS, Tso TC, et al. Roles of tobacco cellulose, sugars, and chlorogenic acid as precursors to catechol in cigarette smoke. J Agric Food Chem 1984; 32: 267-273.
53. Smith CJ, Perfetti TA, King JA,. Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. Inhal Toxicol 2006; 18: 667-77.
54. Lee JM, Yanagawa J, Peebles KA, et al. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008; 66: 208-17.
55. Malkinson AM,. Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res 2005; 31: 57-82.
56. Hecht SS, Kassie F, Hatsukami DK,. Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer 2009; 9: 476-88.
57. Turner MC, Chen Y, Krewski D, et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 2007; 176: 285-90.
58. Dontenwill W, Chevalier HJ, Harke HP, et al. Investigations on the effects of chronic cigarette-smoke inhalation in Syrian golden hamsters. J Natl Cancer Inst 1973; 51: 1781-832.
59. Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 7435-51.
60. United States Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Washington, D.C.: U.S. Department of Health and Human Services, 2010. Chapter 5.
61. Munnia A, Bonassi S, Verna A, et al. Bronchial malondialdehyde DNA adducts, tobacco smoking, and lung cancer. Free Radic Biol Med 2006; 41: 1499-505.
62. 4- ethylthymidine formation in human lung tissue and comparisons with bulky DNA adducts. Mutagenesis 2011; 26: 523-7.
63. Chou PH, Kageyama S, Matsuda S, et al. Detection of lipid peroxidation-induced DNA adducts caused by 4-oxo-2(E)-nonenal and 4-oxo-2(E)-hexenal in human autopsy tissues. Chem Res Toxicol 2010; 23: 1442-8.
64. Boysen G, Hecht SS,. Analysis of DNA and protein adducts of benzo[a]pyrene in human tissues using structure-specific methods. Mutat Res 2003; 543: 17-30.
65. Rojas M, Alexandrov K, Cascorbi I, et al. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM10/0 genotypes. Pharmacogenetics 1998; 8: 109-18.
66. Pfeifer GP, Besaratinia A,. Mutational spectra of human cancer. Hum Genet 2009; 125: 493-506.
67. Kucab JE, Phillips DH, Arlt VM,. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J 2010; 277: 2567-83.
68. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000; 92: 803-11.
69. Denissenko MF, Pao A, Tang M, et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hot spots in P53. Science 1996; 274: 430-2.
70. Tretyakova NT, Matter B, Jones R, et al. Formation of benzo[a]pyrene diol epoxide-DNA adducts at specific guanines within K-ras and p53 gene sequences: stable isotope-labeling mass spectrometry approach. Biochemistry 2002; 41: 9535-44.
71. Matter B, Wang G, Jones R, et al. Formation of diastereomeric benzo[a]pyrene diol epoxide-guanine adducts in p53 gene-derived DNA sequences. Chem Res Toxicol 2004; 17: 731-41.
72. Feng Z, Hu W, Hu Y, et al. Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci USA 2006; 103: 15404-9.
73. 2-propanodeoxyguanosine adducts in human lung by liquid chromatography-electrospray ionization-tandem mass spectrometry. Chem Res Toxicol 2007; 20: 565-71.
74. 2-propanodeoxyguanosine adducts in human leukocyte DNA from smokers and nonsmokers. Chem Res Toxicol 2011; 24: 119-24.
75. Hecht SS, Yuan J-M, Hatsukami DK,. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol 2010; 23: 1001-8.
76. International Agency for Research on Cancer. Dry cleaning, some chlorinated solvents and other industrial chemicals. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 63. Lyon, France: IARC, 1995. 393-407.
77. DeMarini DM,. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat Res 2004; 567: 447-74.
78. de Waard F, Kemmeren JM, van Ginkel LA, et al. Urinary cotinine and lung cancer risk in a female cohort. Br J Cancer 1995; 72: 784-7.
79. Boffetta P, Clark S, Shen M, et al. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 1184-8.
80. Yuan JM, Koh WP, Murphy SE, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res 2009; 69: 2990-95.
81. Hecht SS,. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002; 23: 907-22.
82. Church TR, Anderson KE, Caporaso NE, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009; 18: 260-6.
83. Hecht SS, Chen M, Yagi H, et al. r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4- tetrahydrophenanthrene in human urine: a potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiol Biomarkers Prev 2003; 12: 1501-8.
84. Hecht SS, Carmella SG, Villalta PW, et al. Analysis of phenanthrene and benzo[a]pyrene tetraol enantiomers in human urine: relevance to the bay region diol epoxide hypothesis of benzo[a]pyrene carcinogenesis and to biomarker studies. Chem Res Toxicol 2010; 23: 900-9.
85. Spitz MR, Etzel CJ, Dong Q, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res 2008; 1: 250-4.
86. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008; 98: 270-6.
87. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95: 470-8.
88. Etzel CJ, Kachroo S, Liu M, et al. Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res (Phila Pa) 2008; 1: 255-65.
89. Cronin KA, Gail MH, Zou Z, et al. Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst 2006; 98: 637-40.
90. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst 2011; 103: 1058-68.
91. Etzel CJ, Bach PB,. Estimating individual risk for lung cancer. Semin Respir Crit Care Med 2011; 32: 3-9.